Henry E. Schea
Presidente en Genopoietic SA .
Perfil
Henry E.
Schea is currently the President & General Director at Genopoietic SA since 2009.
Prior to this, he worked at AVAX Technologies, Inc. as the Executive Director-Regulatory Affairs from 2011 to 2016.
He completed his undergraduate degree from the University of Massachusetts in 1976.
Cargos activos de Henry E. Schea
| Empresas | Cargo | Inicio |
|---|---|---|
Genopoietic SA
 Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | Presidente | 21/10/2011 |
Antiguos cargos conocidos de Henry E. Schea.
| Empresas | Cargo | Fin |
|---|---|---|
| AVAX TECHNOLOGIES, INC. | Consejero General | 01/04/2016 |
Formación de Henry E. Schea.
| University of Massachusetts | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Genopoietic SA
Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | Health Technology |
- Bolsa de valores
- Insiders
- Henry E. Schea